These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31219361)

  • 21. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
    Mogensen UM; Gong J; Jhund PS; Shen L; Køber L; Desai AS; Lefkowitz MP; Packer M; Rouleau JL; Solomon SD; Claggett BL; Swedberg K; Zile MR; Mueller-Velten G; McMurray JJV
    Eur J Heart Fail; 2018 Apr; 20(4):760-768. PubMed ID: 29431251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
    Mogensen UM; Køber L; Kristensen SL; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJV;
    Am Heart J; 2017 Jun; 188():35-41. PubMed ID: 28577679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier.
    van der Pol S; de Jong LA; Vemer P; Jansen DEMC; Postma MJ
    Value Health; 2019 Oct; 22(10):1119-1127. PubMed ID: 31563254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
    Vardeny O; Claggett B; Packer M; Zile MR; Rouleau J; Swedberg K; Teerlink JR; Desai AS; Lefkowitz M; Shi V; McMurray JJ; Solomon SD;
    Eur J Heart Fail; 2016 Oct; 18(10):1228-1234. PubMed ID: 27283779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
    Ambrosy AP; Braunwald E; Morrow DA; DeVore AD; McCague K; Meng X; Duffy CI; Rocha R; Velazquez EJ;
    J Am Coll Cardiol; 2020 Sep; 76(9):1034-1048. PubMed ID: 32854838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
    Ehteshami-Afshar S; Mooney L; Dewan P; Desai AS; Lang NN; Lefkowitz MP; Petrie MC; Rizkala AR; Rouleau JL; Solomon SD; Swedberg K; Shi VC; Zile MR; Packer M; McMurray JJV; Jhund PS; Hawkins NM
    J Am Heart Assoc; 2021 Feb; 10(4):e019238. PubMed ID: 33522249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    Rodgers JE
    Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
    Vardeny O; Claggett B; Kachadourian J; Pearson SM; Desai AS; Packer M; Rouleau J; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    Circ Heart Fail; 2018 Apr; 11(4):e004745. PubMed ID: 29643067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analyses of sacubitril-valsartan for heart failure.
    Liu XQ; He LS; Huang JQ; Xiong LJ; Xia C; Lao HY
    Heart Fail Rev; 2021 Sep; 26(5):1119-1130. PubMed ID: 32405811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study.
    Dos Santos MR; Alves MNN; Jordão CP; Pinto CEN; Correa KTS; de Souza FR; da Fonseca GWP; Tomaz Filho J; Costa M; Pereira RMR; Negrão CE; Barretto ACP
    Am Heart J; 2021 Sep; 239():1-10. PubMed ID: 33992607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
    Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF
    Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand.
    Krittayaphong R; Permsuwan U
    Clin Drug Investig; 2021 Oct; 41(10):907-915. PubMed ID: 34533783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation.
    Chang HY; Feng AN; Fong MC; Hsueh CW; Lai WT; Huang KC; Chong E; Chen CN; Chang HC; Yin WH
    J Cardiol; 2019 Oct; 74(4):372-380. PubMed ID: 30982680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience.
    Farmakis D; Bistola V; Karavidas A; Parissis J
    Int J Cardiol; 2016 Nov; 223():781-784. PubMed ID: 27573608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
    McCormack PL
    Drugs; 2016 Mar; 76(3):387-96. PubMed ID: 26873495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.